GlassScriptPhysician profile
Jeffrey Bloom
NPI 1194286773
$9,077.19
in general payments reported to CMS, 2019-2025
21 companies · $2,854 in 2025
The $2,854 reported for 2025 was more than what 85% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $3,648 · 2023: $1,744 · 2024: $720 · 2025: $2,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,365 · Travel and Lodging: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,364.92 |
| Travel and Lodging | $951.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,499.03 | 2022-2025 | Envista Aspire Toric Iol, Stellaris, Vyzulta |
| Alcon Vision LLC | $2,379.22 | 2022-2025 | Unity, Hydrus Microstent, Argos |
| Amgen INC. | $1,106.26 | 2024-2025 | Tepezza |
| Abbvie INC. | $379.07 | 2022-2025 | Durysta |
| Regeneron Healthcare Solutions, INC. | $375.96 | 2022-2025 | Eylea Hd |
| Ani Pharmaceuticals, INC. | $350.49 | 2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Johnson & Johnson Surgical Vision, INC. | $285.77 | 2024-2025 | Tecnis Simplicity, Catalys System |
| Alimera Sciences, INC. | $246.57 | 2023-2024 | Iluvien, Yutiq |
| Horizon Therapeutics Plc | $235.76 | 2022-2023 | Tepezza |
| Astellas Pharma US INC | $195.35 | 2024-2025 | Izervay |
| Microsurgical Technology, INC. | $152.49 | 2022 | |
| Iridex Corporation | $132.67 | 2025 | |
| New World Medical,INC. | $126.78 | 2023 | |
| Allergan, INC. | $121.85 | 2022 | |
| Glaukos Corporation | $119.55 | 2025 | Idosetr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $80.66 | 2025 | |
| Genentech USA, INC. | $54.73 | 2025 | Vabysmo |
| Heidelberg Engineering, INC. | $46.97 | 2025 | Spectralis |
| Apellis Pharmaceuticals, INC. | $42.09 | 2025 | Syfovre |
| Rayner Intraocular Lenses Limited | $17.31 | 2025 | Omidria |
| Harrow Eye, LLC | $16.51 | 2025 | Triesence |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.